• Facebook
  • Twitter
  • LinkedIn
  • Google +
  • RSS
  • Email newsletter

Pharma industry news

Flu shot

First monthly flu vaccination figures released

Posted on: 28 November 2014 | Source: Public Health England

Almost two months since the launch of the seasonal flu vaccine campaign, the first monthly uptake figures show an encouraging start, but Public Health England (PHE) is urging all at risk people not to ‘put off’ getting the vaccination until flu is circulating more widely...

ViiV Healthcare Logo

ViiV Healthcare announces new grants in support of ending mother to child transmission of HIV

Posted on: 27 November 2014 | Source: ViiV Healthcare

Landmark number of grants awarded for 2015 as the Positive Action for Children Fund hits 5 year milestone...

Public Health England

Freshers told ‘it’s not too late’ for MenC vaccine

Posted on: 27 November 2014 | Source: Public Health England

Recent reports of meningitis and septicaemia cases in students...

Boehringer Ingelheim logo

Vargatef® (nintedanib*) approved in the EU for lung cancer patients with advanced adenocarcinoma after first-line chemotherapy

Posted on: 27 November 2014 | Source: Boehringer Ingelheim

Boehringer Ingelheim announced that the European Commission has granted EU marketing authorisation for Vargatef® (nintedanib*), valid for the 28 countries within the EU...

Bristol Myers Squibb logo

Bristol-Myers Squibb receives complete Response Letter from U.S. Food and Drug Administration for daclatasvir, an investigational treatment for Hepatitis C

Posted on: 27 November 2014 | Source: Bristol-Myers Squibb

Bristol-Myers Squibb Company announced that the U.S. Food and Drug Administration has issued a Complete Response Letter regarding the New Drug Application for daclatasvir, an NS5A complex inhibitor, in combination with other agents for the treatment of hepatitis C...

Action required to tackle EU alcohol consumption

Action required to tackle EU alcohol consumption

Posted on: 27 November 2014 | Source: European Alcohol Policy Alliance

Today over 300 representatives from Health Ministries, the European Institutions, public health experts and concerned stakeholders have gathered in Brussels to call on the European Commission President Jean-Claude Juncker and his team to take actions to prevent and reduce the burden of alcohol on European societies...

apitope

Apitope receives Orphan designation in the European Union for ATX-F8-117 for the treatment of Haemophilia A

Posted on: 26 November 2014 | Source: Apitope

Treatment for haemophilia A patients developing Factor VIII inhibitors...

Janssen Pharmaceuticals Logo

Europe’s biopharmaceutical industry faces highest business risks among six key industry sectors, according to first-of-its-kind comparative study

Posted on: 26 November 2014 | Source: Janssen

Economic and societal value of Europe’s biopharmaceutical sector can only be sustained if risks to innovation are adequately rewarded, study concludes...

Cardio3 BioSciences (C3BS) Logo

Cardio3 Biosciences announces the nomination of three co-principal investigators for its chart-2 Phase iii clinical trial of C-Cure® for the treatment of heart failure

Posted on: 26 November 2014 | Source: Cardio3 BioSciences

Cardio3 BioSciences announces the appointment of its three Co-Principal Investigators for the CHART-2 study (Congestive Heart Failure cArdiopoietic Regenerative Therapy), authorized in the United States by the FDA in January, and anticipated to start by the end of 2014...

Janssen Pharmaceuticals Logo

European Commission approves Rezolsta, a new once-daily, fixed-dose HIV therapy combining darunavir and cobicistat

Posted on: 25 November 2014 | Source: Janssen

Janssen-Cilag International NV announced that the European Commission (EC) has approved the use of REZOLSTA® (darunavir/cobicistat) in combination with other antiretroviral (ARV) medicinal products for the treatment of human immunodeficiency virus-1 (HIV-1) infection in adults aged 18 years or older...

Promethera

Promethera Biosciences raises €25.33 million ($31.4 million) in Series C financial round

Posted on: 25 November 2014 | Source: Promethera Biosciences

Promethera Biosciences, a Belgian biotechnology company developing Promethera® HepaStem, a cell-based therapy for the treatment of in-born errors of metabolism and acquired liver diseases, announces the completion of its Series C fundraising round. The company has raised €25.33 million ($31.4 million), including €20.33 million in capital...

Braun

A new survey by Braun reveals how the South East’s blood is boiling over

Posted on: 25 November 2014 | Source: Braun

Nationwide consumer survey sponsored by Braun discovers that regular blood pressure measurement must become a higher priority...